Capivasertib 200mg Tablets — AKT Inhibitor for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Truqap® (Capivasertib) — Targeted AKT Pathway Inhibitor for Advanced Breast Cancer
A Sourcing Guide for Hospitals and Oncology Centres
Truqap® (Capivasertib) is a first-in-class AKT inhibitor indicated, according to the manufacturer’s approved prescribing information, for use in combination with fulvestrant for the treatment of adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN), following progression on endocrine-based therapy. As with all oncology therapies, the decision to prescribe Truqap, including biomarker testing and patient selection, rests entirely with the treating oncologist, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Truqap (Capivasertib) 200mg to hospitals, oncology centres, and pharmacies across India.
Truqap contains Capivasertib, a small-molecule inhibitor that targets all three isoforms of AKT (AKT1, AKT2, and AKT3), a central node in the PI3K/AKT/mTOR signalling pathway.
The PI3K/AKT Pathway and Its Role in Breast Cancer:
According to published oncology literature, the PI3K/AKT/mTOR pathway is one of the most frequently altered signalling pathways in hormone receptor-positive breast cancer. Alterations in PIK3CA (the gene encoding a subunit of PI3K), AKT1, or PTEN (a tumour suppressor that normally restrains this pathway) can lead to constitutive activation of AKT signalling, which drives tumour cell survival, proliferation, and resistance to endocrine therapy.
Capivasertib’s Mechanism: By inhibiting all three AKT isoforms, Capivasertib blocks this constitutively active signalling, according to the manufacturer’s prescribing information. This is particularly relevant in tumours with PIK3CA, AKT1, or PTEN alterations, where the pathway is especially reliant on AKT activity, which is why biomarker testing is required before treatment to identify patients whose tumours carry these specific alterations.
Full prescribing information is available at the FDA label for Capivasertib.
CAPItello-291 Trial (Capivasertib Plus Fulvestrant in Advanced Breast Cancer)
Published in the New England Journal of Medicine (2023), the pivotal CAPItello-291 trial evaluated Capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer that had progressed on or after endocrine therapy. Key results in the biomarker-altered population (PIK3CA/AKT1/PTEN):
This trial formed the basis for regulatory approval of Capivasertib in this indication.
Truqap is available as:
| Presentation | Strength |
|---|---|
| Truqap 200mg Tablets | 200mg per tablet |
Dosing regimen, including tablet count per dose and treatment schedule, is determined by the prescribing oncologist in accordance with the approved prescribing information.
Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer:
Biomarker testing for PIK3CA, AKT1, or PTEN alterations is required before initiating Truqap therapy, per the approved label, using a validated companion diagnostic test.
For detailed indication information refer to MedlinePlus Capivasertib.
First-in-Class AKT Inhibitor for This Setting
Truqap represents a new therapeutic mechanism for hormone receptor-positive, HER2-negative advanced breast cancer, targeting the PI3K/AKT pathway directly rather than relying solely on endocrine or CDK4/6-based approaches.
Evidence-Based Option After CDK4/6 Inhibitor Progression
CAPItello-291 demonstrated benefit regardless of prior CDK4/6 inhibitor exposure, providing oncologists with a further treatment line option for patients whose disease has progressed on standard endocrine-CDK4/6 combinations.
Biomarker-Directed Precision Approach
By requiring PIK3CA, AKT1, or PTEN testing before treatment, Truqap represents a precision oncology approach, directing therapy specifically toward tumours most likely to respond based on their molecular profile.
Dosing of Truqap is determined by the prescribing oncologist according to the approved label. General administration information from the manufacturer’s prescribing information includes:
Monitoring (per manufacturer prescribing information):
Full dosing guidelines are available in the manufacturer’s official prescribing information and should always be followed exactly as directed by the treating oncologist.
Truqap is prescribed by oncologists for:
Truqap is prescribed by oncologists specialising in breast cancer management. A.K. Pharma supplies Truqap to hospitals and oncology centres across Delhi and India.
Common side effects reported in clinical trials include diarrhoea, rash, nausea, fatigue, and elevated blood glucose.
Serious side effects include:
Hyperglycaemia: AKT pathway inhibition is associated with elevated blood glucose; blood glucose monitoring is recommended per the approved prescribing information, particularly in patients with pre-existing diabetes or risk factors.
Diarrhoea: Reported as a common adverse event in clinical trials; management per the treating physician’s guidance, potentially including dose modification per the approved label.
Cutaneous Adverse Reactions: Rash and other skin reactions have been reported; dermatological monitoring is recommended per the manufacturer’s prescribing information.
Full side effect information is available at FDA Capivasertib Safety Information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all oncology medicines including Truqap under manufacturer-recommended conditions ensuring product integrity for every supply.
Truqap (Capivasertib) is manufactured by AstraZeneca. Capivasertib received regulatory approval in 2023 for use in combination with fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations. A.K. Pharma supplies only genuine Truqap sourced from authorised distributors.
Q. What is Truqap used for?
Truqap (Capivasertib) is used in combination with fulvestrant to treat adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations, following progression on endocrine-based therapy.
Q. What is the generic name of Truqap?
The generic name of Truqap is Capivasertib, an AKT inhibitor targeting the PI3K/AKT/mTOR signalling pathway.
Q. Why is biomarker testing required before starting Truqap?
Truqap is approved specifically for tumours with PIK3CA, AKT1, or PTEN alterations, which make the AKT pathway a key driver of tumour growth. Testing confirms whether a patient’s tumour carries one of these alterations before treatment is considered.
Q. Is Truqap used alone or in combination with other medicines?
Truqap is used in combination with fulvestrant, an endocrine therapy, as established in the CAPItello-291 clinical trial and per the approved prescribing information.
Q. Is Truqap available in India?
Truqap can be supplied to hospitals and oncology centres across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Truqap in India?
Truqap price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Truqap from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Truqap in bulk?
Yes. A.K. Pharma supplies Truqap in bulk to hospitals and oncology centres across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and dosing, should be made by a qualified healthcare professional in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
